Outcomes after Bone Marrow Versus Peripheral Blood Matched Unrelated Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based GVHD Prophylaxis | Synapse
March 3, 2026
Outcomes after Bone Marrow Versus Peripheral Blood Matched Unrelated Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based GVHD Prophylaxis
Key Points
Outcomes indicate that bone marrow transplantation leads to lower rates of graft-versus-host disease (GVHD) compared to peripheral blood transplantation.
Recent findings suggest a significant reduction of GVHD incidences by 30% when using posttransplant cyclophosphamide-based prophylaxis.
Observational analysis across multiple medical centers compared the efficacy and safety of donor sources in hematopoietic cell transplantation.
This data highlights the importance of donor type in improving post-transplant outcomes, implying a need for further studies in diverse populations.